Role of dose exposure and inflammatory status in a single center, real-world analysis of sunitinib in patients with metastatic renal cell carcinoma

Marco Maruzzo; Umberto Basso; Alberto Diminutto; Anna Roma; Fable Zustovich; Antonella Brunello; Pasquale Fiduccia; Alberto Banzato; Filiberto Zattoni; Vittorina Zagonel

doi:10.2217/fon.16.14

Role of dose exposure and inflammatory status in a single center, real-world analysis of sunitinib in patients with metastatic renal cell carcinoma

Marco Maruzzo, Umberto Basso, Alberto Diminutto, Anna Roma, Fable Zustovich, Antonella Brunello, Pasquale Fiduccia, Alberto Banzato, Filiberto Zattoni, Vittorina Zagonel

Istituto Oncologico Veneto

Research output: Contribution to journal › Article › peer-review

Abstract

Aim, patients & methods: To evaluate the real-world setting use of sunitinib, we reviewed data of our patients from January 2007 to December 2014. Results: In 114 patients, sunitinib was used as first-line TKI. Out of 110 evaluable patients, 5 complete responses, 37 partial responses, 42 stabilizations were reported. Median progression-free survival and overall survival (OS) were 14.3 and 28.4 months. Patients who received ≥4 full-dose cycles had a better OS (p = 0.02). A neutrophil-lymphocyte ratio

Original language	English
Pages (from-to)	909-919
Number of pages	11
Journal	Future Oncology
Volume	12
Issue number	7
DOIs	https://doi.org/10.2217/fon.16.14
Publication status	Published - Apr 1 2016

Keywords

dose exposure
neutrophil-lymphocite ratio
real world
renal cell carcinoma
sunitinib
survival

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.2217/fon.16.14

Cite this

@article{cadd5066eee84723bca2a07f16f62128,

title = "Role of dose exposure and inflammatory status in a single center, real-world analysis of sunitinib in patients with metastatic renal cell carcinoma",

abstract = "Aim, patients & methods: To evaluate the real-world setting use of sunitinib, we reviewed data of our patients from January 2007 to December 2014. Results: In 114 patients, sunitinib was used as first-line TKI. Out of 110 evaluable patients, 5 complete responses, 37 partial responses, 42 stabilizations were reported. Median progression-free survival and overall survival (OS) were 14.3 and 28.4 months. Patients who received ≥4 full-dose cycles had a better OS (p = 0.02). A neutrophil-lymphocyte ratio ",

keywords = "dose exposure, neutrophil-lymphocite ratio, real world, renal cell carcinoma, sunitinib, survival",

author = "Marco Maruzzo and Umberto Basso and Alberto Diminutto and Anna Roma and Fable Zustovich and Antonella Brunello and Pasquale Fiduccia and Alberto Banzato and Filiberto Zattoni and Vittorina Zagonel",

year = "2016",

month = apr,

day = "1",

doi = "10.2217/fon.16.14",

language = "English",

volume = "12",

pages = "909--919",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "7",

}

TY - JOUR

T1 - Role of dose exposure and inflammatory status in a single center, real-world analysis of sunitinib in patients with metastatic renal cell carcinoma

AU - Maruzzo, Marco

AU - Basso, Umberto

AU - Diminutto, Alberto

AU - Roma, Anna

AU - Zustovich, Fable

AU - Brunello, Antonella

AU - Fiduccia, Pasquale

AU - Banzato, Alberto

AU - Zattoni, Filiberto

AU - Zagonel, Vittorina

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Aim, patients & methods: To evaluate the real-world setting use of sunitinib, we reviewed data of our patients from January 2007 to December 2014. Results: In 114 patients, sunitinib was used as first-line TKI. Out of 110 evaluable patients, 5 complete responses, 37 partial responses, 42 stabilizations were reported. Median progression-free survival and overall survival (OS) were 14.3 and 28.4 months. Patients who received ≥4 full-dose cycles had a better OS (p = 0.02). A neutrophil-lymphocyte ratio

AB - Aim, patients & methods: To evaluate the real-world setting use of sunitinib, we reviewed data of our patients from January 2007 to December 2014. Results: In 114 patients, sunitinib was used as first-line TKI. Out of 110 evaluable patients, 5 complete responses, 37 partial responses, 42 stabilizations were reported. Median progression-free survival and overall survival (OS) were 14.3 and 28.4 months. Patients who received ≥4 full-dose cycles had a better OS (p = 0.02). A neutrophil-lymphocyte ratio

KW - dose exposure

KW - neutrophil-lymphocite ratio

KW - real world

KW - renal cell carcinoma

KW - sunitinib

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=84962277425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962277425&partnerID=8YFLogxK

U2 - 10.2217/fon.16.14

DO - 10.2217/fon.16.14

M3 - Article

AN - SCOPUS:84962277425

VL - 12

SP - 909

EP - 919

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 7

ER -

Role of dose exposure and inflammatory status in a single center, real-world analysis of sunitinib in patients with metastatic renal cell carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this